In the CT26 model, tumor-bearing mice treated with anti-CTLA-4 in combination with anti-PD-1 exhibited an increase in the frequency of CD8+ T cells, but not of CD4+ T cells amongst TIL (72% increase in CD8+ T cell frequency relative to control treatment, p<0.01, Fig 4A). The gene discussed is CD8A; the disease is neoplasm.